# BridgeBio Pharma, Inc.: Form SCHEDULE 13D/A, filed Apr 2, 2026

- Company: [BridgeBio Pharma, Inc.](/companies/bbio.md) (CIK 1743881)
- Form: SCHEDULE 13D/A
- Filed: 2026-04-02
- Accepted by EDGAR: Apr 2, 2026, 18:40 ET
- Period: not reported
- Accession: 0000905148-26-001499
- Inline XBRL: no
- Main document: https://www.sec.gov/Archives/edgar/data/1743881/000090514826001499/xslSCHEDULE_13D_X02/primary_doc.xml
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1743881/000090514826001499/

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1743881/000090514826001499/xslSCHEDULE_13D_X02/primary_doc.xml

Filed Apr 2, 2026.
Source: SEC EDGAR, the filing index for accession 0000905148-26-001499. Last ingested by Listed: Nov 3, 2026, 19:31 ET. No prices; not investment advice.